Biomarker Panel for Cardiotoxicity Prediction in Drug Development

The patent changes the parameters used for cardiotoxicity prediction by introducing a multi-marker panel system that measures multiple biomarkers simultaneously (such as troponin, BNP, and other cardiac-specific markers) rather than relying on single-marker or traditional methods. This parameter expansion enables more accurate prediction of cardiotoxicity while allowing drug development to proceed with reliable data, resolving the contradiction between prediction accuracy and development efficiency

The patent creates a universal biomarker panel that can assess multiple aspects of cardiac safety simultaneously through a single integrated assessment system. This multi-functional approach allows the same set of markers to predict various types of cardiotoxicity effects, improving reliability without requiring separate assessment procedures for different cardiac parameters, thus maintaining drug development productivity

The patent combines multiple biomarker assessments into a single integrated diagnostic panel that evaluates several cardiac markers simultaneously. By merging the detection of different biomarkers (troponin, BNP, cytokines, etc.) into one comprehensive test system, the patent achieves high measurement precision for cardiotoxicity detection while avoiding the complexity of running separate tests for each marker, thus resolving the contradiction between detection accuracy and diagnostic complexity

The patent performs preliminary identification of at-risk compounds early in drug development using the biomarker panel, allowing potential cardiotoxicity issues to be detected before extensive clinical trials begin. This preliminary action enables early decision-making about compound viability, improving detection accuracy for problematic compounds while simplifying the overall diagnostic process by filtering out unsafe candidates before more complex assessments are needed